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Abstract. A large number of classic antineoplastic agents are 
derived from plants. Euphorbia tirucalli L. (Euphorbiaceae) 
is a subtropical and tropical plant, used in Brazilian folk 
medicine against many diseases, including cancer, yet little is 
known about its true anticancer properties. The present study 
evaluated the antitumor effect of the tetracyclic triterpene 
alcohol, euphol, the main constituent of E. tirucalli in a panel 
of 73 human cancer lines from 15 tumor types. The biological 
effect of euphol in pancreatic cells was also assessed. The 
combination index was further used to explore euphol interac-
tions with standard drugs. Euphol showed a cytotoxicity effect 
against several cancer cell lines (IC50 range, 1.41-38.89 µM), 
particularly in esophageal squamous cell (11.08 µM) and 
pancreatic carcinoma cells (6.84 µM), followed by prostate, 
melanoma, and colon cancer. Cytotoxicity effects were seen 
in all cancer cell lines, with more than half deemed highly 
sensitive. Euphol inhibited proliferation, motility and colony 
formation in pancreatic cancer cells. Importantly, euphol 
exhibited synergistic interactions with gemcitabine and pacli-
taxel in pancreatic and esophageal cell lines, respectively. To 
the best of our knowledge, this study constitutes the largest 
in vitro screening of euphol efficacy on cancer cell lines and 
revealed its in vitro anti-cancer properties, particularly in 
pancreatic and esophageal cell lines, suggesting that euphol, 
either as a single agent or in combination with conventional 
chemotherapy, is a potential anti-cancer drug.
Introduction
The 20th century saw an extraordinary breakthrough of natural 
products, especially regarding the application of plants in the 
field of oncology, enabling the discovery of several substances 
currently used in cancer therapy (1-3). Plants secondary metabo-
lites and their semi-synthetic derivatives play an important role 
in current oncology treatment. Of the 250 drugs considered as 
basic and essential by the World Health Organization (WHO), 
11% are derived from medicinal plants (4). Within this list, there 
are drugs that constitute the backbone of cancer therapy as vinka 
alcaloids (vinblastine and vincristine), camptothecin derivatives 
(topotecan and irinotecan), epipodophyllotoxin (etoposide and 
teniposide), and, more recently, taxanes (docetaxel, paclitaxel 
and cabazitaxel). Despite these facts, it is estimated that less than 
2% of higher plants have been analyzed for their antineoplastic 
activity, due to the time and resource intensive phenotype-based 
drug discovery process (1,5).
Brazil has one of largest plant diversity in world, with a 
myriad of opportunities for phytochemicals production, yet; 
only approximately 8% it has been studied (6,7). Extracts 
of species from the genus Euphorbia (Euphorbiaceae) are 
used by traditional healers for the treatment of ulcers, warts 
and other diseases (7,8). The Euphorbia genus is worldwide 
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spread, used as decorative plant and comprises thousands of 
different species. Some species of this genus have triggered 
interest about potential antineoplastic activity, partly based on 
anedoctic reports stemming from traditional medicine (7-9). 
Interestingly, a derived from E. peplus, the ingenol mebutate 
(ingenol‑3‑angelate, PEP005, Picato®; LEO Pharma A/S, 
Ballerup, Denmark), was recently approved by the FDA 
for actinic keratosis treatment, a premalignant lesion for 
sun-related squamous-cell carcinoma (10,11).
Amongst the species under Euphorbia genus, E. tirucalli 
has a large use in traditional medicine (7). The main 
constituent of E. tirucalli sap is euphol, a tetracyclic triterpene 
alcohol, which has shown anti‑inflammatory, antiviral, and 
analgesic properties (12,13). In mice model of acute colitis 
and arthritic, euphol showed an anti‑inflammatory effect (14). 
Euphol was also reported to exhibit antinociceptive properties 
in both inflammatory and neuropathic pain of mice and rats 
models (15). Moreover, euphol showed to inhibit the reverse 
transcriptase in human immunodeficiency virus type 1.
Recently, euphol was suggested to display an anti-cancer 
effect. In vitro studies in breast and gastric tumor cell reported 
that euphol decreased cell viability (16,17). In an in vivo study 
of ascitic Ehrlich tumor model, treatment with E. tirucalli 
hydroalcoholic extract (ETHE) leads a higher animal 
survival (18). These studies have increased the therapeutic 
interest of E. tirucalli compounds, mainly euphol in oncology. 
On the other hand, some reports suggest that the exposure to 
E. tirucalli crude can be a risk factor for Burkitt's lymphoma, 
since it act as a genotoxic agent, especially when it contains 
phorbol ester (7,19). Therefore, further studies are needed to 
elucidate the potential therapeutic use of euphol.
Herein, we aimed to study the antitumor effect of euphol 
on a large panel of human cancer cell lines from a high variety 
of tumor types, in order to provide insight into the tailoring 
designing of euphol-based therapies for cancer patients.
Materials and methods
Cell lines and cell culture. Seventy-three immortalized human 
cancer cell lines from 15 solid tumor models were analysed 
(Table I). The U87MG was purchased from American Type 
Culture Collection (ATCC HTB-14; Manassas, VA, USA). 
Authentication of all cell lines was carried out by the Center 
for Molecular Diagnostics of Barretos Cancer Hospital (São 
Paulo, Brazil) as previously reported (20). Shorthly, short 
tandem repeat (STR) DNA typing was performed according 
to the International Reference Standard for Authentication of 
Human Cell Lines previously described (21). The identity of all 
cell lines was confirmed by genotyping, with the exception of 
U373, which was shown to be a sub-clone of U251 cell line. All 
the cell lines were maintained in Dulbecco's modified Eagle's 
medium (DMEM 1X, high glucose; Gibco; Thermo Fisher 
Scientific, Inc., Waltham, MA, USA) or RPMI‑1640 (Gibco; 
Thermo Fisher Scientific, Inc.) supplemented with 10% fetal 
bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.) 
and 1% penicillin/streptomycin solution (P/S; Gibco; Thermo 
Fisher Scientific, Inc.), at 37˚C and 5% CO2.
Preparation and compound dilution. The sap from E. tirucalli 
L. (accepted name record 82539-Sp. Pl. 452 1753.) was 
initially extracted with hexane and the resulting precipitate 
was extracted with n-butanol. The most lipophilic compounds 
present in the butanol fraction were purified by means of 
high performance liquid chromatography analysis (HPLC). 
Further purification of the compounds was carried out 
using a Sephadex G75 column in a mixture of hexane-ethyl 
acetate. Recrystallization of the acetate fraction from butanol 
gave 3.5 g crystals, comprising euphol acetate and filtrate 
(1.5 g). The chemical structure of the euphol, representeted 
in Fig. 1, was determined by elemental analyses of 1H NMR 
and 13C NMR spectral data, and by comparison with their 
respective authentic compounds using Chemdraw software 
version 7.0 (22,23) (PubChem CID: 441678). The 1H NMR 
(500 MHz) and 13C NMR (126 MHz) spectra were recorded 
on a Bruker 500 MHz instrument. The MS spectra were 
recorded on a Perkin Elmer instrument, model API 150 and 
run in ES-MS positive mode: MH+ 427 m/e, MH+ _H2O 
409 m/e. The NMR parameters were 13C NMR (CDCl3): 15.7 
(C29), 15.8 (C18), 17.9 (C26), 19.1 (C21), 19.2 (C6), 20.4 (C19), 
21.7 (C11), 24.9 (C30), 25.0 (C23), 25.9 (C27), 28.0 (C2, C7), 
28.2 (C28), 28.3 (C16), 30.0 (C15), 31.1 (C12), 35.4 (C1), 35.7 
(C22), 36.1 (C20), 37.5 (C10), 39.2 (C4), 44.3 (C13), 49.9 (C17), 
50.2 (C14), 51.2 (C5), 79.2 (C3), 125.4 (C24), 131.1 (C25), 133.8 
(C9), 134.3 (C8) and 1H NMR (CDCl3): 0.75 (3H, s, H-18), 
0.80 (3H, s, H-29), 0.85 (3H, d, H-21), 0.87 (3H, s, H-30), 0.95 
(3H, s, H-19), 1.00 (3H, s, H-28), 1.50 (3H, s, H-26), 1.68 (3H, s, 
H-27), 3.23 (1H, dd, H-3), 5.09 (1H, bt, H-24). The tetracyclic 
triterpene euphol used in this study showed >95% purity.
The extract fraction was initially dissolved in dimethyl 
sulfoxide (DMSO) at a concentration of 50 mg/ml and stored 
at ‑20˚C. The intermediate dilutions of the experimental 
compound were prepared to obtain a concentration of 
1% DMSO.
Cell viability assay. The cytotoxicity effect of euphol was 
assessed by Cell Titer 96 Aqueous cell proliferation assay (MTS 
assay; Promega Corporation, Madison, WI, USA), following 
the manufacturer's instructions as previous described (20,24). 
For experiments, the cells (third and fifth passage) were 
plated into 96-well plates (until a maximum 5x103 cells/well). 
The plate was incubated overnight for optimal attachment 
of adherent lines, and then placed under low serum-starved 
conditions for 24 h (DMEM supplemented with 0.5% of FBS). 
Subsequently, the cells were treated with increasing concen-
trations of the test compound diluted in DMEM (0.5% FBS) 
and incubated for 72 h. The control groups received the same 
amount of vehicle (1% DMSO, final concentration). Growth 
of tumoral cells was quantified by ability of living cells to 
reduce the yellow dye MTS to a blue formazan product. Two 
hours before the end of incubation, 10 µl of MTS were added 
to each well, and the plate further incubated for 2 h at 37˚C. 
Absorbance was measured in automatic microplate reader 
Varioskan ( Thermo Fisher Scientific, Inc.) at 490 nm. The 
response to euphol treatment was assessed by standardizing 
treated groups to the untreated control, and were expressed 
as a percentage relatively to control cells, in DMSO alone 
(considered as 100% viability) ± SD.
IC50 determination. The results of absorbance values of treated 
cells were converted to percentage of cell viability in cells in 
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Table I. Euphol IC50 values and percentual of GI at a fixed euphol concentration (15 µM).
Cell line Mean IC50 SD GI (%) at 15 µMa GIS SD Tumor type
T47D 38.89 9.27 31.8 R 7.0 Breast
MDA-MB-231 9.08 0.87 56.7 MS 14.0 
MDA-MB-468 30.89 6.22 27.5 R 10.3 
BT20 8.96 2.92 66.7 HS 2.9 
HS587T 18.15 8.91 61.4 HS 25.5 
MCF-7 18.76 3.43 52.6 MS 14.1 
MCF7/AZ 33.42 5.01 22.8 R 11.6 
JHU-O22 26.35 7.31 5.6 R 5.1 Head and neck
HN13 8.89 6.53 69.2 HS 6.0 
SCC25 6.65 3.54 74.2 HS 3.6 
SCC4 19.82 1.95 31.5 R 9.9 
SCC14 15.81 2.63 53.3 MS 6.5 
FADU 20.17 2.68 46.7 MS 9.2 
SW480 5.79 0.05 80.7 HS 4.1 Colon
SW620 10.02 4.54 68.8 HS 9.2 
CO115 9.58 2.35 74.1 HS 8.3 
HCT15 5.47 0.81 92.3 HS 1.6 
HT29 6.52 1.37 78.1 HS 4.4 
SK-CO-10 17.53 7.13 58.0 MS 11.9 
DLD1 2.56 1.18 80.0 HS 3.9 
LOVO 11.49 2.39 63.2 HS 5.5 
DIFI 11.38 2.86 67.9 HS 4.3 
Caco2 35.19 5.11 25.1 R 10.0 
U87-MG 26.41 3.19 6.7 R 12.7 Glioma
U373 30.48 3.51 10.0 R 12.1 
U251 29.01 7.82 23.3 R 9.5 
GAMG 8.73 1.87 90.1 HS 0.5 
SW1088 27.12 2.55 7.2 R 7.2 
SW1783 19.62 1.42 44.2 MS 9.6 
RES186 16.70 3.72 41.6 MS 14.8 
RES259 10.34 4.08 70.6 HS 8.6 
KNS42 19.94 0.27 23.3 R 6.2 
UW479 15.26 4.83 53.4 MS 15.3 
SF188 5.98 2.42 74.4 HS 4.3 
PC-3 11.95 4.47 66.7 HS 9.6 Prostate
LNCaP 1.41 0.45 67.7 HS 4.6 
T24 30.72 0.30 9.2 R 3.1 Blader
5637 4.83 1.61 88.3 HS 2.4 
HT1376 25.25 0.41 9.9 R 8.5 
MCR 7.40 2.77 59.1 MS 7.0 
DAOY 5.72 1.37 79.3 HS 1.5 
ONS76 21.72 2.07 10.9 R 16.1 Meduloblastoma
JEG3 16.65 0.86 61.5 HS 7.6 Choriocarcinome
A431 17.79 3.41 40.2 MS 14.8 Epidermoid
H292 13.25 2.16 52.6 MS 5.7 Lung
SKMES1 25.62 0.79 24.9 R 7.4 
A549 11.01 3.11 60.0 HS 10.4 
SK-LU-1 22.83 2.06 4.2 R 8.7 
SIHA 24.74 3.65 6.7 R 5.9 Cervical
CASKI 24.74 2.67 19.3 R 13.1 
C33A 21.32 4.21 52.6 MS 1.7 
HELA 17.55 3.41 44.6 MS 18.0 
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with presence of the vehicle (DMSO), which were used as 
control, corresponding to 100% survival. The analysis of the 
non-linear regression curve using GraphPad PRISM version 7 
(GraphPad Software, Inc., La Jolla, CA, USA) the was carried 
out on results of viability, yielding an equation used to calculate 
the concentration of substance required to produce 50% reduc-
tion in cell viability (IC50) as previous determined (25,26).
Drug combination studies. Combination studies were done 
with fixed concentrations (determinated IC50 value) of standard 
chemotherapeutic paclitaxel (Sigma-T7402; Sigma-Aldrich; 
Merck KGaA, Darmstadt, Germany) and gemcitabine 
hydrochloride (Sigma-G6423; Sigma-Aldrich; Merck KGaA, 
Darmstadt, Germany) (data not shown), exposed simultane-
ously to increasing concentrations of euphol. The drug 
interactions were evaluated by the combination index (CI) that 
was calculated by the Chou-Talalay equation, which takes into 
account both the potency (Dm or IC50) and the shape of the 
dose-effect curve (27,28), using CalcuSyn software version 2.0 
(Biosoft, Ferguson, MO, USA). In CI analysis, synergy was 
defined as CI values significantly lower than 1.0; antagonism 
as CI values significantly higher than 1.0; and additivity as CI 
values equal to 1.0 at drug IC50 value for each cell line.
Proliferation assay. The proliferation effect of euphol was 
assessed by BrdU assay kit (Roche Applied Science, Mannheim, 
Germany) following the manufacturer's instructions. In brief, 
5x103 cells/well were seeded in a 96‑well, flat‑bottom plate. 
The plate was incubated overnight for optimal attachment 
of adherent lines, and then placed under low serum-starved 
conditions for 24 h (DMEM-0.5% FBS). Subsequently, the 
cells were treated with increasing concentrations of the test 
compound diluted in DMEM (0.5% FBS) and incubated for 
72 h. The control groups received the same amount of vehicle 
(1% DMSO, final concentration). Therefore, the proliferation 
effect was assessed by BrdU assay kit following the manu-
facturer's instructions. Experiments were done in triplicate in 
three independent experiments for each cell line.
Table I. Continued.
Cell line Mean IC50 SD GI (%) at 15 µMa GIS SD Tumor type
KYSE30 3.52 1.28 71.7 HS 5.7 Oesophagus
KYSE70 8.77 0.74 78.8 HS 1.8 
KYSE270 10.71 3.95 66.9 HS 12.5 
KYSE410 4.35 2.03 85.5 HS 3.4 
Mia PaCa-2 8.46 0.39 79.9 HS 3.2 Pancreatic
PANC-1 21.47 1.83 49.0 MS 6.6 
PSN-1 3.71 0.17 63.5 HS 4.9 
BXPC-3 5.47 1.64 84.9 HS 2.8 
Capan-1 16.33 2.06 61.0 HS 8.5 
COLO858 14.02 2.94 55.8 MS 7.5 Melanoma
COLO679 8.93 4.45 66.8 HS 9.0 
A375 9.67 1.86 63.6 HS 3.9 
WM1617 16.32 2.95 55.1 MS 11.3 
WM9 9.67 4.11 75.8 HS 6.9 
WM852 7.61 1.08 77.4 HS 4.0 
WM278 27.46 1.48 30.5 R 18.1 
WM35 12.40 3.57 63.9 HS 14.2 
WN793 5.96 0.26 73.3 HS 8.0 
SKMEL-37 10.07 0.06 69.0 HS 9.9 
PA-1 7.97 3.03 68.3 HS 3.4 Ovary
SW626 30.40 5.61 23.9 R 11.5 
aGI was defined in comparison with untreated controls. Samples exhibiting more than 60% GI in the presence of 15 µM euphol were classified 
as HS; MS when located between 40-60%; and R when showing less than 40%. GIS, Growth Inhibition Score; SD, standard deviation; GI, 
Growth Inhibition; HS, highly sensitive; MS, moderately sensitive; R, resistant.
Figure 1. Chemical structure of euphol.
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The criterion of GI to ascertain the cell line sensibility to 
euphol was previously described (29). Mean GI values was 
calculated at fixed dose of 15 µM of euphol (concentration 
closer to the mean IC50 value for all cell lines) and established 
as 100%-percentage of viable cells at this dose. Samples 
exhibiting more than 60% GI in the presence of 15 µM euphol 
were classified as highly sensitive (HS); moderately sensitive 
(MS) when located between 40-60%; and resistant when 
showing less than 40%. All the assays were done in triplicate 
and repeated at least three times for each cell line.
Wound‑healing migration assay. Cell migration proper-
ties were evaluated by wound-healing assay, as previsously 
described by our group (26,30). The pancreatic cancer cell 
lines, Mia-Pa-Ca-2 and Panc-1, were plated in 6-well plates and 
grown to confluence. A sterile tip was used to create a scratch 
in monolayer cells. Cells were then incubated with euphol at 
8.46 and 21.47 µM. The ʻ woundedʼ areas were photographed by 
phase contrast microscopy (Model IX71; Olympus Corporation, 
Tokyo, Japan) to evaluate wound closure (0, 24, 48 and 72 h). 
The migration rate of individual cells was determined by 
measuring the distances covered from the initial time to the 
selected time-points (bar of distance tool, DP2-BSW Olympus 
version 2.2). The percentage of the relative migration distance 
was calculated as wound area at a given time compared to the 
initial wound surface. Pictures shown are representative of 
three independent experiments performed in triplicates.
Colony formation‑assay. Inhibition of anchorage-independent 
was assesed by soft-type-agar assay as reported (30). We placed 
1 ml of acellular solution of 0.6% agar (combining equal volumes 
of 1.2% Noble agar with 2x concentrated DMEM with 20% FBS) 
into a six-well plate and incubated at 37˚C for 10 min; 2x104 cells 
of Mia-Pa-Ca-2 and Panc-1 were homogenized in solution 
containing DMEM supplemented with 0.35% agar (upper layer 
agar; equal volumes of 0.7% Noble agar and 2X concentrated 
DMEM with 20% FBS) and seeded onto acellular coating. 
After solidification 0.5 ml of DMEM medium + 10% FBS was 
added. The medium was changed every two days, and DMEM 
medium + 0.5% euphol at 3 and 10 µM was added. The cells 
were incubated at 37˚C in a humidified atmosphere of 5% CO2 
for 20 days; colonies formed were stained with 0.05% crystal 
violet for 15 min. Photo-documented colonies were analyzed 
using the Image J Software. The assay was performed in two 
biological replicates and the experiments were done in duplicate.
Statistical analysis. The results of in vitro experiments are 
expressed as mean ± standard deviation (SD) of three inde-
pendent experiments. IC50 values were obtained by nonlinear 
regression. We applied Student's t-test for comparing two 
different conditions whereas two-way analysis of variance with 
Tukey's post hoc test was used for assessing differences between 
more groups. P<0.05 was considered to indicate a statistically 
significant difference. All statistical analyzes were performed 
using GraphPad PRISM version 7 (GraphPad Software, Inc.).
Results
Euphol promotes cytotoxity in human cancer cell lines. 
The antitumor effect of euphol in vitro was assessed using 
MTS assay on 73 human cancer lines from 15 solid tumor 
models (breast, colon, bladder, prostate, lung, pancreas, 
esophageal, head and neck, cervical, epidermoid carcinoma, 
meduloblastoma, placental choriocarcinoma, ovarian carci-
noma, glioblastoma, and melanoma) (Table I). We generated 
complete dose-response curves and IC50 values for this 
euphol treatment. Among each tumor type, the distinct cell 
lines exhibited a heterogeneous profile of response to euphol 
(Fig. 2A). The mean of IC50 values was 15.14 (6.47 µg/ml), but 
varied significantly between individual cell lines with up to 
a more than 27-fold difference in the IC50 values [IC50 range: 
1.41-38.89 µM (0.60-16.62 µg/ml)]. Esophageal squamous 
cell carcinoma and pancreatic carcinomas showed the most 
sensitive profiles (IC50 mean 11.08 and 6.84 µM, respectively, 
Fig. 2A and Table I), followed by prostate, melanoma and 
colon cancer cell lines.
To allow a better classification of the cell lines response 
to euphol, we determined their GI. We found that 50.68% 
(37/77) were classified as HS, 21.92% (16/73) were MS, and 
27.4% (20/77) were resistant (Fig. 2B and Table I). Esophageal 
(100%), prostate (100%) and pancreatic (80%) cancer models 
showed a higher percentage of HS cell lines. At variance, 
glioma (54.5%) followed by breast tumor type (42%) has the 
most cancer cell lines scored as resistant.
Biological effect of euphol on pancreatic cancer cell lines. We 
further investigated the biological effect of euphol on pancre-
atic cancer cell lines, the most sensitive tumoral type in our 
study. To determine whether the effect of euphol on cancer 
cells is cytotoxic or cytostatic, its effect was also evaluated on 
the proliferation of pancreatic cell lines by BrdU incorpora-
tion. As shown in Fig. 3A, euphol exhibited dose-dependent 
effects on proliferation of pancreatic cancer cell lines (Panc-1 
and Mia‑Pa‑Ca‑2) but varied significantly between individual 
cell lines. In both cancer cell lines, low doses of euphol slightly 
decreased proliferation and the dose of 17.51 µM was able to 
inhibit almost 50% of the proliferation.
Euphol also exhibited dose-dependent effects on 
cell viability on pancreatic cancer cell lines (Panc-1 and 
Mia-Pa-Ca-2). Although euphol decreased the proliferation, 
the strongest inhibition of proliferation was seen at 35.1 µM 
concentration of euphol after 72 h, with almost 39.4% for 
Mia-Pa-Ca-2 cells and 51% for Panc-1 cells (Fig. 3A), whereas 
the same concentration suppressed cell viability of Mia-Pa-Ca-2 
cells by 10.7% and Panc-1 cells by 22.4% (Fig. 3B). Thus, 
comparing the effects on cell viability in concentrations of the 
same magnitude, euphol seemed to inhibit growth through a 
more cytotoxic than cytostatic fashion.
Next, we investigated its biological effect on pancreatic 
cancer cell lines. In untreated conditions for both cell lines 
(Mia-Pa-Ca-2 and Panc-1, complete close up of the wound 
took longer than 72 h, suggesting that these cell lines have 
an intrinsic low migratory capability. Those two cells lines 
were treated with euphol at 8.46 and 21.47 µM. In spite of the 
low migratory feature of the cells, euphol treatment signifi-
cantly inhibited cell migration in Mia-Pa-Ca-2 at 72 h when 
compared to control cells (Fig. 3C). We could not evaluate the 
effect of euphol in Panc-1 cell motility, since this cell present 
an inherent low motility phenotype hampered an adequate 
assessment of any inhibition. The findings suggest that euphol 
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has a cytotoxic effect but were not able to inhibit the migration 
of this cell line (Fig. 3D).
In addition to cell proliferation (anchorage-dependent 
growth) and cell migration, colony formation (anchorage-inde-
pendent growth) is one of the typical characteristics of the 
metastatic potential of cancer cells in vitro and strongly 
correlates with tumorigenesis in vivo (31). Therefore, we evalu-
ated the effect of euphol in anchorage-independent growth 
of Panc-1 cancer cells. Panc-1 cells formed colonies on agar 
after 20 days of incubation, and the presence of euphol at IC50 
value resulted in a significant suppression of number and size 
of colonies (P<0.05; Fig. 3E). The ability to form colony was 
reduced by 90% compared to the untreated control. Similarly, 
we proceeded the same way with Mia-Pa-Ca-2 cell line, 
however we can not observe the colonies formation even in 
the control condition suggesting a low tumorigenic potential 
of this cell line (data not shown).
Euphol potentiates chemotherapeutic‑induced decrease in cell 
viability. We also evaluated the potential combinatorial value 
of euphol in the context of standard esophageal and pancreatic 
tumor therapy. We found that euphol and gemcitabine combi-
nation treatment showed a synergistic effect (CI<1) in 50% 
of pancreatic cells lines investigated (mean CI values, range: 
0.76-0.8; Table II), being the combination more effective than 
single agents. Likewise, euphol was able to synergistically sensi-
tize most esophageal cells lines to paclitaxel treatment (mean CI 
values, range: 0.37-0.55; Table III).
Discussion
In the present study, we investigated the cytotoxity effects of 
euphol on a large panel of 73 human cancer cell lines, derived 
from 15 solid tumor models including breast, colon, bladder, 
prostate, lung, pancreas, esophagus, head and neck, cervical 
cancer as well as glioma and melanoma. We observed that 
euphol exhibited dose-dependent cytotoxic effects on all 
human cancer cell lines tested with the highest effect (reduced 
viability) for pancreas and esophageal cancer lines, followed by 
prostate, melanoma and colon cancer cell lines. According to 
Figure 2. Effect of euphol compound on human cancer cell lines survival. (A) Cellular viability was measured at 72 h by MTS assay. The results were expressed 
as the mean percentage ± SD of three independent experiments of viable cells relatively to the DMSO alone (considered as 100% viability). The IC50values 
were calculated by nonlinear regression analysis using GraphPad Prism software. Data represent the mean of at least three independent experiments done in 
triplicate. (B) Growth inhibition (GI) profile of human cancer‑derived cell lines exposed to euphol. Bars represent the cell viability at 15 µM of euphol. Colors 
represent the GI score classification. Blue (HS, highly sensitive); Yellow (MS, moderate sensitive) and Red (R, resistant).
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the American National Cancer Institute criteria, euphol would 
be a promising compound for further analysis since its IC50 
values were lower than 30 µg/ml (http://www.cancer.gov) (32). 
The cytotoxic and/or growth-inhibition effects of euphol were 
identified at low IC50 values, being lower than 30 µg/ml for 71 
out 73 cancer cell lines tested. Our results are in agreement 
with earlier in vitro reports that suggested E. tirucalli crude 
extracts or euphol may have antitumoral effect. The relative 
toxicity of the E. tirucalli crude extracts on Mia-Pa-Ca-2 was 
also evaluated by Munro et al, which demonstrated that meth-
anol extracts exerted a significant decrease in cell viability 
at 25 µg/ml (33). Also, Choene et al, investigated E. tirucali 
crude extracts that contains different types of secondary 
metabolites mainly terpenes and flavonoids, and reported its 
effect on breast cancer (MCF-7 and MDA-MB-231) cell cycle 
arrest (34). Lin et al, reported the effect of euphol in gastric 
cancer cell lines (CSN, CS12, AGS and MKN45) with an IC50 
values of 49.6, 12.8, 14.7 and 14.4 (µg/ml), respectively (17). 
The authors also reported that euphol induced apoptosis by 
upregulation of ERK signaling (17). Another study analyzing 
the T47D breast cancer cells showed that euphol has an anti-
proliferative activity, with IC50 values of 260 µM (16). The 
results suggest a cytostatic effect for euphol that induced GI by 
cell cycle arrest at the G0/G1 phase. In our study we observed 
a lower IC50 value (38.89 µM) in the T47D cells, yet, also 
above the limite considered effective by NCI. It is worthy of 
note that although the extract of E. tirucalli containing 64% 
euphol (7), in our study breast cancer cell lines were the less 
responsive to euphol in which the HPLC purity revealed above 
95%. This finding seems to be in accordance with the potential 
of the compound found in phytochemical evaluation, which 
indicated that it is a tetracyclic triterpene alcohol (7,35).
To gain more insight into the role played by euphol in 
tumorigenesis, we investigated the biological effect of euphol 
on pancreatic cancer cell lines. Euphol inhibited cell prolifera-
tion (anchorage-dependent growth) as well as colony formation 
(anchorage-independent growth) of pancreatic cancer cells. We 
also showed that euphol inhibits cell migration of Mia-Pa-Ca-2 
Figure 3. Effect of euphol on pancreatic cancer cell. (A) Cell proliferation was measured with BrdU assay and (B) cell viability was measured with MTS 
assay on Mia-Pa-Ca-2 and Panc-1 cell lines after 72 h of euphol treatment. The proliferation of the untreated cells and the viability of the untreated cells were 
regarded as 100%. Results shown are the means ± SD of three independent experiments. Cell motility of (C) Mia-Pa-Ca-2 and (D) Panc-1 was evaluated with 
wound healing assay. In this assay, a standardized scratch (wound) was applied to cell monolayers and digital images, of the same areas, were taken at several 
time points (0, 24, 48 and 72 h) after euphol treatment. The distance in pixels was measured in each time point and the percentage of wound closure was 
calculated according to the distance on initial time point (0 h). Figures are representative of three independent experiments. **Differences with P<0.005 in the 
Student's t test were considered statistically significant. (E) Effect of euphol on colony formation assay in pancreatic cancer cells. Panc‑1 cells were seeded 
and grown in soft agar medium containing euphol. The number of colonies in each well was determined 20 days after initial euphol treatment. The figures are 
representative of two experiments performed in duplicate. *Differences with P<0.05 in the Student's t test were considered statistically significant.
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cancer cell line. One of the suitable molecular cancer targets 
is protein kinase (ERK), which is an important factor in the 
regulation of cell migration of numerous cell types. The ERK 
pathway inhibitors PD98059 and U0126 inhibit the migration 
of diverse cell types in response to cell matrix proteins, such 
as fibronectin, vitronectin and collagen (36). Supporting a 
possible role of ERK inhibition on migration modulation by 
euphol, Passos et al, showed that, at the intracellular level, 
euphol reduced TPA-induced extracellular signal-regulated 
ERK activation in skin inflammation in mice (13). However, 
these data are in disagreement with Lin et al, which showed 
that euphol selectively induced gastric cancer cells apoptosis 
by activation of ERK signaling (17). Taken together, these find-
ings provided further support that euphol effect may depend 
on the cellular context and showed that further investigation 
regarding euphol in other cancer cell lines and in other experi-
mental model are required.
In addition, we investigated the combination of euphol to 
chemotherapy in pancreas and esophageal cancer lines and 
we found that euphol when combined with a gemcitabine 
and paclitaxel treatment seems to have a synergistic effect 
(chemo-sensitization) leading to lower doses of therapeutic 
agents. This synergy (chemo-sensitization) is of major interest 
since those two standard chemotherapy drugs formed the 
therapy backbone for those cancers, the level of responses seen 
in practice is still suboptimal and there is an urgent need for 
improvement (37,38).
The present study constitutes, to our knowledge, the first 
largest screening of euphol efficacy on human cancer cell 
lines. We showed that euphol could be a promising agent on 
large number of tumor types, in particularly in esophageal 
and pancreatic cancer. One important limitation of the present 
study is the lack of normal counterpart cells of the distinct 
tumor types evaluated. Therefore, additional studies are 
warranted to address this topic. This study also revealed the 
inhitbition/reduction of some hallmark events, such as prolif-
eration and migration as part of the mechanism of action of 
this compound on pancreatic cancer cells. Finally, the euphol 
also showed synergistic interactions with chemotherapeutic 
drugs used in clinical practice. Our results provide insights 
for further studies suggesting euphol as an interesting antineo-
plastic alone or in combination for cancer treatment.
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